NONRECEPTOR TYROSINCE KINASE BMX/ETK AS A THERAPEUTIC TARGET IN BREAST CANCER

$127,500FY2008Department of the ArmyDOD

Beth Israel Deaconess Medical Center, Inc.

Investigators